Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration and European Medicines Agency TARRYTOWN, N.Y., April 07, 2024 -- Regeneron...

Related Keywords

United States ,New York ,San Diego ,California ,Tarrytown ,American ,Vesna Tosic ,Sundar Jagannath ,Tammy Allen ,International Staging System ,Nasdaq ,Drug Administration ,Regeneron Genetics Center ,Regeneron Pharmaceuticals Inc ,Clinical Development Program ,Linkedin ,American Association For Cancer Research ,Myeloma Center ,European Medicines Agency ,Exchange Commission ,American Association ,Cancer Research ,Annual Meeting ,Multiple Myeloma Center ,Tisch Cancer Center ,Mount Sinai ,New York City ,African American ,Fast Track Designation ,Priority Review ,Linvoseltamab Phase ,Clinical Development ,Regeneron Genetics ,Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,